Summary
Generics in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The European generics market had total revenues of $73.0bn in 2018, representing a compound annual growth rate (CAGR) of 6.7% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 2.3% between 2014 and 2018, to reach 58.5% of total pharma volume.
- For pharmaceutical companies in the UK market, Brexit continues to cause major uncertainty, primarily in regard to the future of the regulatory process, human resources, and compliance legislation.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Europe
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Europe
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Europe generics market with five year forecasts by both value and volume
Reasons to buy
- What was the size of the Europe generics market by value in 2018?
- What will be the size of the Europe generics market in 2023?
- What factors are affecting the strength of competition in the Europe generics market?
- How has the market performed over the last five years?
- How large is Europe’s generics market in relation to its regional counterparts?
'
Table of Contents
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. Which players have been most successful in the recent past (1-3 years)?
7.3. What mergers or acquisitions have taken place in the last year?
8 Company Profiles
8.1. Teva Pharmaceutical Industries Limited
8.2. Mylan N.V.
8.3. Pfizer Inc.
8.4. Sanofi SA
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
List of Tables
Table 1: Europe generics market value: $ million, 2014-18
Table 2: Europe generics market volume: % of total pharma, 2014-18
Table 3: Europe generics market geography segmentation: $ million, 2018
Table 4: Europe generics market value forecast: $ million, 2018-23
Table 5: Europe generics market volume forecast: % of total pharma, 2018-23
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Mylan N.V.: key facts
Table 10: Mylan N.V.: Annual Financial Ratios
Table 11: Mylan N.V.: Key Employees
Table 12: Pfizer Inc.: key facts
Table 13: Pfizer Inc.: Annual Financial Ratios
Table 14: Pfizer Inc.: Key Employees
Table 15: Pfizer Inc.: Key Employees Continued
Table 16: Sanofi SA: key facts
Table 17: Sanofi SA: Annual Financial Ratios
Table 18: Sanofi SA: Key Employees
Table 19: Sanofi SA: Key Employees Continued
Table 20: Europe size of population (million), 2014-18
Table 21: Europe gdp (constant 2005 prices, $ billion), 2014-18
Table 22: Europe gdp (current prices, $ billion), 2014-18
Table 23: Europe inflation, 2014-18
Table 24: Europe consumer price index (absolute), 2014-18
Table 25: Europe exchange rate, 2014-18
List of Figures
Figure 1: Europe generics market value: $ million, 2014-18
Figure 2: Europe generics market volume: % of total pharma, 2014-18
Figure 3: Europe generics market geography segmentation: % share, by value, 2018
Figure 4: Europe generics market value forecast: $ million, 2018-23
Figure 5: Europe generics market volume forecast: % of total pharma, 2018-23
Figure 6: Forces driving competition in the generics market in Europe, 2018
Figure 7: Drivers of buyer power in the generics market in Europe, 2018
Figure 8: Drivers of supplier power in the generics market in Europe, 2018
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Europe, 2018
Figure 10: Factors influencing the threat of substitutes in the generics market in Europe, 2018
Figure 11: Drivers of degree of rivalry in the generics market in Europe, 2018
